Journal of Cancer and Tumor International

Even though lung cancer is one of the most prevalent diseases, with an increasing incidence as well as the continued occurrence of morbidity and death, our clinical practice needs to consider a wide range of factors when determining the most appropriate treatment option for patients. The advanced stage of lung cancer is the most prevalent type of lung cancer, and it has already spread to other parts of the body, including distant and regional locations. This is especially true in developing nations like Indonesia. In addition to the fact that surgery is a curative option for these cancers, the advanced stage has a limited reaction whenever we perform a surgical procedure; there are still many opportunities for the tumour to spread and metastasise. This review aims to explore the evolving treatment landscape of advanced-stage lung cancer, focusing on molecular targeted therapy approaches and overcoming resistance mechanisms.

When it comes to these advanced instances, our current perspective is that chemotherapy and radiotherapy have already been announced for several years with unfavourable clinical outcomes, regardless of whether the follow-up is for a short period of time or for a longer period of time.A significant advancement in the field of lung cancer treatment methods has been achieved with the implementation of molecular targeted therapy approaches. The use of these strategies has the potential to substantially raise the rate of progression-free survival as well as the overall response rate of the first-line drugs that are administered to patients who have been diagnosed with lung cancer. Nonetheless, the persistent problem of the development of resistance to molecular targeted therapy is something that must be taken into consideration when treating patients with advanced lung cancer. In order to circumvent this issue, it is necessary to either find new pharmacological targets or to use drug delivery systems that combine multiple agents.